Repetitive group inspection of production lots is considered to develop the failure censored plan with minimal expected sampling effort using prior information. Optimal reliability test plans are derived for the family of log-location-scale lifetime distributions, whereas a limited beta distribution is assumed to model the proportion nonconforming, p. A highly efficient and quick step-by-step algorithm is proposed to solve the underlying mixed nonlinear programming problem. Conventional repetitive group plans are often very effective in reducing the average sample number with respect to other inspection schemes, but sample sizes may increase under certain conditions such as high censoring. The inclusion of previous knowledge from past empirical results contributes to drastically reduce the amount of sampling required in life testing. Moreover, the use of expected sampling risks significantly improves the assessment of the actual producer and consumer sampling risks. Several tables and figures are presented to analyse the effect of the available prior evidence about p. The results show that the proposed lot inspection scheme clearly outperforms the standard repetitive group plans obtained under the traditional approach based on conventional risks. Finally, an application to the manufacture of integrated circuits is included for illustrative purposes.

Docetaxel plus prednisone is the current standard of care in first-line chemotherapy for metastatic hormone-refractory prostate cancer. However, there is no agent proven as effective after progression to standard docetaxel-based therapy. Platins and capecitabine have shown activity in this setting. A total of 14 patients were included in this prospective, single-center trial. All patients had progressed to first-line docetaxel-based treatment. Patients received oxaliplatin 100 mg/sqm on D1 and capecitabine 1000 mg/sqm/bid on days 1 to 14 every 21 days. Median number of cycles was 3. No unexpected toxicity was observed. Only grade 3 toxicity reported was grade 3 anemia. Of the 14 patients, 3 presented grade 2 neuropathy which was spontaneously resolved. Prostate-specific antigenresponse rate was 57%, with a median time to progression of 14.5 weeks, and overall survival of 24 weeks. In the second-line setting, after receiving docetaxel-based chemotherapy, the combination of oxaliplatin and capecitabine offers promising activity with an excellent safety profile.

Fulvestrant is a selective estrogen receptor (ER) down-regulator; fulvestrant inhibits ER dimerization [1] and reduces ER’s half-life [2]. In preclinical models, fulvestrant inhibited cell growth of the DU145 prostate cancer (PCa) cell line through an ER-β-dependent mechanism [3]. Metastatic PCa expresses ER-β mainly in metastases to the lymph nodes and bones [4].